Literature DB >> 7989386

Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin.

P Faunø1, O Suomalainen, V Rehnberg, T B Hansen, K Krøner, S Soimakallio, E Nielsen.   

Abstract

We compared the efficacy and safety of low-molecular-weight heparin with that of low-dose unfractionated heparin in the prevention of venous thromboembolism after total knee arthroplasty in a prospective, randomized, multicenter trial. One hundred and eighty-five patients were randomly assigned to two groups: ninety-two received low-molecular-weight heparin (forty milligrams of enoxaparin the evening before the operation and once a day subsequently) and ninety-three received unfractionated heparin (5000 international units the evening before the operation and three times a day thereafter). The prophylaxis was continued until bilateral ascending venography was performed six to nine days after the operation or, if venography was not done, until the eighth postoperative day. Venography revealed a prevalence of deep-vein thrombosis of 27 per cent (twenty-five of ninety-three patients) in the group that received unfractionated heparin and 23 per cent (twenty-one of ninety-two patients) in the group that received low-molecular-weight heparin. The difference was not significant (p = 0.6). Five patients (5 per cent) who received unfractionated heparin and 3 patients (3 per cent) who received low-molecular-weight heparin had a deep-vein thrombosis in the proximal veins. Two patients who received unfractionated heparin and one who received low-molecular-weight heparin had clinical symptoms suggestive of a pulmonary embolism. None of these three patients had a positive ventilation-perfusion scan. There were no deaths, major bleeding episodes, or wound hematomas necessitating operative intervention or discontinuation of the anticoagulation in the series.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989386     DOI: 10.2106/00004623-199412000-00007

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

Review 1.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

2.  Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.

Authors:  R Ferriols-Lisart; F Ferriols-Lisart; V Jiménez-Torres
Journal:  Pharm World Sci       Date:  2002-06

Review 3.  Osteoarthritis of the knee.

Authors:  David Scott; Anna Kowalczyk
Journal:  BMJ Clin Evid       Date:  2007-09-01

4.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

5.  Use of tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement.

Authors:  Yasir J Sepah; Masood Umer; Tashfeen Ahmad; Faria Nasim; Muhammad Umer Chaudhry; Muhammad Umar
Journal:  J Orthop Surg Res       Date:  2011-05-21       Impact factor: 2.359

6.  Does a single loading dose of tranexamic acid reduce perioperative blood loss and transfusion requirements after total knee replacement surgery? A randomized, controlled trial.

Authors:  Ratul Kundu; Anjan Das; Sandip Roy Basunia; Tapas Bhattacharyya; Surajit Chattopadhyay; Anindya Mukherjee
Journal:  J Nat Sci Biol Med       Date:  2015 Jan-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.